VBLT Vascular Biogenics Ltd. Stock Quote

VBLT [NASD]

Index	-	P/E	-	EPS (ttm)	-0.56	Insider Own	22.99%	Shs Outstand	47.90M	Perf Week	0.00%
Market Cap	86.30M	Forward P/E	-	EPS next Y	-0.53	Insider Trans	0.00%	Shs Float	37.18M	Perf Month	-20.96%
Income	-22.70M	PEG	-	EPS next Q	-0.14	Inst Own	23.90%	Short Float	4.79%	Perf Quarter	23.13%
Sales	0.80M	P/S	107.88	EPS this Y	12.60%	Inst Trans	0.97%	Short Ratio	1.60	Perf Half Y	48.36%
Book/sh	0.78	P/B	2.32	EPS next Y	1.90%	ROA	-47.20%	Target Price	-	Perf Year	30.22%
Cash/sh	0.77	P/C	2.35	EPS next 5Y	-	ROE	-61.80%	52W Range	0.90 - 3.17	Perf YTD	-4.23%
Dividend	-	P/FCF	-	EPS past 5Y	10.40%	ROI	-51.60%	52W High	-42.90%	Beta	0.90
Dividend %	-	Quick Ratio	5.20	Sales past 5Y	-	Gross Margin	72.40%	52W Low	101.11%	ATR	0.27
Employees	38	Current Ratio	5.20	Sales Q/Q	100.00%	Oper. Margin	-	RSI (14)	35.33	Volatility	11.88% 13.12%
Optionable	Yes	Debt/Eq	0.07	EPS Q/Q	10.90%	Profit Margin	-	Rel Volume	0.39	Prev Close	1.79
Shortable	Yes	LT Debt/Eq	0.05	Earnings	-	Payout	-	Avg Volume	1.11M	Price	1.81
Recom	1.80	SMA20	-18.94%	SMA50	-20.29%	SMA200	19.18%	Volume	437,345	Change	1.12%

Jun-27-19

Initiated

Oppenheimer

Outperform

Mar-09-18

Downgrade

Chardan Capital Markets

Buy → Neutral

$25 → $3

Mar-08-18

Downgrade

Piper Jaffray

Overweight → Neutral

Mar-08-18

Downgrade

H.C. Wainwright

Buy → Neutral

Nov-06-17

Reiterated

Chardan Capital Markets

Buy

$20 → $25

Jun-28-16

Initiated

H.C. Wainwright

Buy

$11

Nov-09-15

Initiated

Piper Jaffray

Overweight

Oct-23-15

Reiterated

Chardan Capital Markets

Buy

$25 → $27.50

Sep-28-15

Reiterated

ROTH Capital

Buy

$13 → $22

Sep-22-15

Initiated

Chardan Capital Markets

Buy

$25

Sep-21-15

Upgrade

JMP Securities

Mkt Perform → Mkt Outperform

May-22-15

Initiated

ROTH Capital

Buy

$13

Mar-04-21 07:00AM	VBL Therapeutics Announces Peer-reviewed Publication of Positive Results of Pre-specified Interim Analysis of OVAL, a Phase 3 Registration Enabling Study of VB-111 in Ovarian Cancer GlobeNewswire
Mar-01-21 07:00AM	VBL Therapeutics Announces Patient Dosing Initiated in Randomized, Controlled and Blinded Trial of VB-111 in Patients with Recurrent Glioblastoma Multiforme GlobeNewswire
Feb-22-21 01:08PM	Vascular Biogenics' Ovarian Cancer Gene Therapy Study To Continue, Recommends An Independent Committee Benzinga -12.55%
07:00AM	VBL Therapeutics Announces Data Safety Monitoring Committee Provides Green Light to Advance the OVAL Phase 3 Registration Enabling Study of VB-111 in Ovarian Cancer GlobeNewswire
Jan-27-21 07:00AM	VBL Therapeutics Treats First Patient in Phase 2 Randomized Controlled Study of VB-201 in COVID-19 Patients GlobeNewswire
Jan-19-21 05:42AM	Here's Why We're Watching Vascular Biogenics' (NASDAQ:VBLT) Cash Burn Situation Simply Wall St.
Jan-15-21 07:15AM	VBL Therapeutics Enters Into Ordinary Share Purchase Agreement of up to $20 Million With Aspire Capital Fund, LLC GlobeNewswire
Dec-29-20 07:00AM	VBL Therapeutics Announces First Patient in Europe in the OVAL Trial GlobeNewswire
Dec-07-20 07:00AM	VBL Therapeutics Announces Insider Buying GlobeNewswire
Nov-18-20 12:31AM	Vascular Biogenics Ltd. (NASDAQ:VBLT) Analysts Just Slashed Next Year's Revenue Estimates By 16% Simply Wall St.
Nov-16-20 08:25AM	Vascular Biogenics (VBLT) Reports Q3 Loss, Tops Revenue Estimates Zacks
07:11AM	Vascular Biogenics: Q3 Earnings Insights Benzinga
07:00AM	VBL Therapeutics Reports Third Quarter 2020 Financial Results and Provides Corporate Update GlobeNewswire
06:30AM	Vascular Biogenics Ltd. to Host Earnings Call ACCESSWIRE
05:50AM	How Much Is Vascular Biogenics Ltd. (NASDAQ:VBLT) Paying Its CEO? Simply Wall St.
Nov-15-20 10:09AM	The Week Ahead In Biotech: The Vaccine Updates, Drug Presentations, And FDA Decisions That Will Move The Markets Benzinga
Nov-13-20 10:09AM	Earnings Outlook For Vascular Biogenics Benzinga +6.31%
Nov-05-20 07:00AM	VBL Therapeutics to Present at the H.C. Wainwright 6th Annual Israel Conference GlobeNewswire
Nov-02-20 07:00AM	VBL Therapeutics to Report Third Quarter 2020 Financial Results on November 16 GlobeNewswire
Oct-15-20 07:00AM	VBL Therapeutics Announces Additional New European Patent in the MOSPD2 Platform Technology, This Time for Treatment of Cancer GlobeNewswire
Oct-13-20 07:00AM	VBL Therapeutics Announces Appointment of Marc Kozin as Vice Chairman of Board of Directors GlobeNewswire
Oct-12-20 07:00AM	Newly Granted European Patent Protects VBL Therapeutics' Anti-MOSPD2 Antibodies for Inflammation Until at least July 2036 GlobeNewswire
Sep-29-20 08:00AM	VBL Therapeutics to Present at the Chardan 4th Annual Genetic Medicines Conference GlobeNewswire +5.36%
Sep-21-20 04:01PM	VBL Therapeutics to Present at the Oppenheimer Fall Healthcare Life Sciences & MedTech Summit GlobeNewswire
Sep-17-20 02:01PM	Who Has Been Buying Vascular Biogenics Ltd. (NASDAQ:VBLT) Shares? Simply Wall St.
Sep-15-20 08:00AM	VBL Therapeutics to Provide an Update on the OVAL Study Today at the H. C. Wainwright 22nd Annual Global Investment Conference GlobeNewswire +6.06%
Sep-11-20 08:00AM	VBL Presents Human Proof-of-Concept Data That Show the Potential of its Novel anti-MOSPD2 Monoclonal Antibodies for Multiple Sclerosis at the MS Virtual 2020 Meeting GlobeNewswire +18.42%
Sep-10-20 09:25AM	VBL Therapeutics Announces Enrollment of the First Patients in the Phase 2 Clinical Trial of VB-111 in Metastatic Colorectal Cancer GlobeNewswire
Sep-08-20 08:00AM	VBL Therapeutics Announces Successful Completion of Pre-IND Meeting with FDA Regarding Proposed Clinical Development of VB-601 GlobeNewswire -5.13%
Aug-13-20 10:35AM	Vascular Biogenics (VBLT) Reports Q2 Loss, Misses Revenue Estimates Zacks
07:30AM	Vascular Biogenics: Q2 Earnings Insights Benzinga
07:00AM	VBL Therapeutics Announces Second Quarter 2020 Financial Results and Provides Corporate Update GlobeNewswire
Aug-12-20 08:00AM	VBL Therapeutics Announces Second Successful Pre-planned Interim Analysis with a Positive Data Safety Monitoring Committee Review Looking at OS - the Primary Endpoint of the OVAL Phase 3 Potential Registration Study of VB-111 in Ovarian Cancer GlobeNewswire
Aug-06-20 12:30PM	Earnings Preview: Vascular Biogenics (VBLT) Q2 Earnings Expected to Decline Zacks
Aug-03-20 08:00AM	VBL Therapeutics to Report Second Quarter 2020 Financial Results on August 13 GlobeNewswire
Jul-15-20 04:16AM	MORNING BID-Fog, stall ... rally Reuters
Jun-25-20 09:02AM	Growth Investors: Industry Analysts Just Upgraded Their Vascular Biogenics Ltd. (NASDAQ:VBLT) Revenue Forecasts By 24% Simply Wall St.
Jun-22-20 08:00AM	VBL Therapeutics Presents MOSPD2 Bi-Specific Antibody Activity and Potential Survival Benefit for Solid Tumors in Late Breaking Research Session of the AACR Virtual Annual Meeting GlobeNewswire
Jun-04-20 07:00AM	VBL Presents New Data on the Potential of its Novel anti-MOSPD2 Monoclonal Antibodies for Rheumatoid Arthritis at the EULAR 2020 Congress GlobeNewswire
Jun-01-20 07:00AM	VBL Presents Positive Interim Data from the OVAL Phase 3 Pivotal Study in Ovarian Cancer at the ASCO20 Annual Meeting, Showing 58% or Higher Objective Response Rate GlobeNewswire
May-28-20 09:44AM	3 Strong Buy Penny Stocks That Offer Massive Potential Gains TipRanks +6.96%
May-18-20 09:16AM	Earnings Update: Vascular Biogenics Ltd. (NASDAQ:VBLT) Just Reported And Analysts Are Boosting Their Estimates Simply Wall St.
07:00AM	VBL Therapeutics to Present New Data on Its MOSPD2 Bispecific Antibody Program for Solid Tumors in Late Breaking Research Session of the AACR Virtual Annual Meeting GlobeNewswire
May-15-20 12:28PM	This Just In: Analysts Are Boosting Their Vascular Biogenics Ltd. (NASDAQ:VBLT) Outlook for This Year Simply Wall St.
May-14-20 08:38AM	Recap: Vascular Biogenics Q1 Earnings Benzinga
08:25AM	Vascular Biogenics (VBLT) Reports Q1 Loss, Tops Revenue Estimates Zacks
07:00AM	VBL Therapeutics Announces First Quarter 2020 Financial Results and Provides Corporate Update GlobeNewswire
May-13-20 06:23PM	VBL Therapeutics Closes $8.1 Million Registered Direct Offering to Key Current Shareholders Priced At-the-Market under Nasdaq Rules GlobeNewswire
May-12-20 07:00AM	VBL Therapeutics Closes $10.0 Million Registered Direct Offering and Announces $8.1 Million Registered Direct Offering to Key Current Shareholders, Each Priced At-the-Market under Nasdaq Rules GlobeNewswire
May-07-20 12:30PM	Earnings Preview: Vascular Biogenics (VBLT) Q1 Earnings Expected to Decline Zacks -21.47%
09:22AM	VBL Therapeutics Announces $10.0 Million Registered Direct Offering Priced At-the-Market under Nasdaq Rules GlobeNewswire
May-06-20 07:00AM	VBL Presents New Data on MOSPD2 Antibodies as Potential Treatment for NASH and Colitis at DDW GlobeNewswire +8.67%
May-05-20 10:45AM	Introducing Vascular Biogenics (NASDAQ:VBLT), The Stock That Tanked 77% Simply Wall St. +9.49%
May-04-20 07:00AM	VBL Therapeutics to Report First Quarter 2020 Financial Results on May 14 GlobeNewswire
07:00AM	VBL First-in-class MOSPD2 Antibodies Show Potential for Treatment for CNS Inflammation GlobeNewswire
Apr-21-20 07:00AM	VBL Therapeutics Awarded 3.2 Million NIS Non-Dilutive Grant by the Israel Innovation Authority for VB-111 GlobeNewswire
Apr-06-20 07:00AM	VBL Therapeutics Announces New Milestone Event in the VB-201 Collaboration for Veterinary Use GlobeNewswire +11.21%
Apr-02-20 09:00AM	Following Positive Interim Analysis, VB-111 Global Study in Ovarian Cancer to Extend to Japan via Collaboration with NanoCarrier GlobeNewswire +6.90%
Mar-26-20 09:39PM	Edited Transcript of VBLT earnings conference call or presentation 19-Mar-20 12:30pm GMT Thomson Reuters StreetEvents +27.20%
07:57AM	VBL Therapeutics Announces Positive Outcome of the Interim Analysis in the OVAL Phase 3 Ovarian Cancer Pivotal Study GlobeNewswire
Mar-21-20 09:02AM	Earnings Update: Vascular Biogenics Ltd. (NASDAQ:VBLT) Just Reported And Analysts Are Trimming Their Forecasts Simply Wall St.
Mar-19-20 10:33AM	Vascular Biogenics: Q4 Earnings Insights Benzinga +8.33%
08:15AM	Vascular Biogenics (VBLT) Reports Q4 Loss, Lags Revenue Estimates Zacks
07:00AM	VBL Therapeutics Announces Year Ended December 31, 2019 Financial Results and Provides Corporate Update GlobeNewswire
06:30AM	Vascular Biogenics Ltd. to Host Earnings Call ACCESSWIRE
Mar-12-20 12:30PM	Analysts Estimate Vascular Biogenics (VBLT) to Report a Decline in Earnings: What to Look Out for Zacks -11.38%
Mar-02-20 08:00AM	VBL Therapeutics to Report Fourth Quarter 2019 Financial Results on March 19 GlobeNewswire
Feb-20-20 08:00AM	VBL Therapeutics Announces the Launch of a New Clinical Trial of VB-111 Combined with the Checkpoint Inhibitor, Nivolumab, in Metastatic Colorectal Cancer GlobeNewswire
Feb-03-20 08:00AM	VBL Therapeutics to Present at the BIO CEO & Investor Conference GlobeNewswire
Jan-27-20 08:29AM	Will VBL Continue to Surge Higher? Zacks +5.41%
Jan-20-20 02:28PM	We're Hopeful That Vascular Biogenics (NASDAQ:VBLT) Will Use Its Cash Wisely Simply Wall St.
Jan-08-20 08:00AM	VBL Therapeutics Announces Publication of Phase 2 and Phase 3 Data of VB-111 in Recurrent Glioblastoma Supporting Continued Development in Investigator-Sponsored Study GlobeNewswire
Nov-28-19 10:44PM	Should You Sell Vascular Biogenics Ltd. (VBLT)? Insider Monkey
Nov-21-19 08:00AM	VBL Therapeutics to Present Data on New Investigator-Sponsored Phase 2 Trial of VB-111 in Recurrent Glioblastoma at the 2019 Society for Neuro-Oncology Annual Meeting GlobeNewswire +6.31%
Nov-14-19 08:15AM	Vascular Biogenics (VBLT) Reports Q3 Loss, Lags Revenue Estimates Zacks
07:00AM	VBL Therapeutics Announces Third Quarter 2019 Financial Results GlobeNewswire
Nov-07-19 10:30AM	Vascular Biogenics (VBLT) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release Zacks
Nov-06-19 08:00AM	VBL Therapeutics Announces New IND for an Investigator-Sponsored Phase 2 Trial of VB-111 in Recurrent Glioblastoma GlobeNewswire
Oct-31-19 08:00AM	VBL Therapeutics to Report Third Quarter 2019 Financial Results on November 14 GlobeNewswire
Oct-03-19 03:39PM	Easy Come, Easy Go: How Vascular Biogenics (NASDAQ:VBLT) Shareholders Got Unlucky And Saw 80% Of Their Cash Evaporate Simply Wall St.
Aug-13-19 08:25AM	Vascular Biogenics (VBLT) Reports Q2 Loss, Misses Revenue Estimates Zacks
07:15AM	VBL Therapeutics Announces Second Quarter 2019 Financial Results GlobeNewswire
06:30AM	Vascular Biogenics Ltd. to Host Earnings Call ACCESSWIRE
Aug-06-19 10:30AM	Vascular Biogenics (VBLT) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release Zacks
Aug-05-19 08:00AM	VBL Therapeutics to Report Second Quarter 2019 Financial Results on August 13 GlobeNewswire -8.59%
Jul-31-19 02:43PM	Do Insiders Own Shares In Vascular Biogenics Ltd. (NASDAQ:VBLT)? Simply Wall St.
Jul-22-19 08:00AM	VBL Therapeutics Announces Modiin Production Facility Received a GMP Compliance Certificate Following EU QP Audit GlobeNewswire
Jun-04-19 07:00AM	VBL Therapeutics to Provide Additional Details on the New VB-111 Data Presented Earlier This Week at ASCO, in a Presentation at the 2019 BIO International Convention Today GlobeNewswire
Jun-03-19 08:00AM	VBL Final Phase 1/2 Study Results Presented at ASCO Demonstrate VB-111 Dose Dependent Increase in Overall Survival and 58% CA-125 Response Rate in Platinum-Resistant Ovarian Cancer GlobeNewswire -8.03%
08:00AM	Radiographic Analysis of VB-111 Phase 2 and 3 Clinical Trials in Recurrent Glioblastoma Shows Survival Benefit Associated with Objective Responses and Distinct Signature of VB-111 Activity GlobeNewswire
May-23-19 09:00AM	VBL Therapeutics Announces Presentations at the 2019 ASCO Annual Meeting and the BIO International Convention GlobeNewswire
May-16-19 07:52AM	Edited Transcript of VBLT earnings conference call or presentation 15-May-19 12:30pm GMT Thomson Reuters StreetEvents +7.44%
May-15-19 08:15AM	Vascular Biogenics (VBLT) Reports Q1 Loss, Misses Revenue Estimates Zacks
07:09AM	Vascular Biogenics: 1Q Earnings Snapshot Associated Press
07:00AM	VBL Therapeutics Announces First Quarter 2019 Financial Results GlobeNewswire
May-14-19 05:16PM	Vascular Biogen Expected to Lose 12 Cents a Share TheStreet.com
May-08-19 10:30AM	Will Vascular Biogenics (VBLT) Report Negative Earnings Next Week? What You Should Know Zacks
May-06-19 08:00AM	VBL Therapeutics to Report First Quarter 2019 Financial Results on May 15 GlobeNewswire
Apr-04-19 02:33PM	Those Who Purchased Vascular Biogenics (NASDAQ:VBLT) Shares Three Years Ago Have A 54% Loss To Show For It Simply Wall St.
Mar-29-19 07:19AM	Edited Transcript of VBLT earnings conference call or presentation 28-Mar-19 12:30pm GMT Thomson Reuters StreetEvents

Vascular Biogenics Ltd., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of treatments for cancer and immune/inflammatory indications. The company's program is based on its proprietary vascular targeting system platform technology, which utilizes genetically targeted therapy to destroy newly formed or angiogenic blood vessels. Its lead product candidate is VB-111, a gene-based biologic that is in Phase 3 clinical trials for the treatment of recurrent glioblastoma, an aggressive form of brain cancer; and in Phase 1/2 clinical trials for recurrent platinum-resistant ovarian cancer, as well as in Phase 2 clinical trials to treat GI tumors and has completed phase 2 clinical trial for the treatment of thyroid cancer. In addition, it is developing VB-511, an anti-angiogenic candidate for oncology; and VB-211 and VB-411, which are pro-angiogenic candidates for the treatment of peripheral vascular diseases. Further, the company is developing VB-201, a Lecinoxoid-based compound used to treat atherosclerosis that has completed phase II clinical, as well as in pre-clinical stage for the treatment of NASH and renal fibrosis. It is also developing VB-601 and 611 for immuno-oncology and anti-inflammatory applications. The company was formerly known as Medicard Ltd. and changed its name to Vascular Biogenics Ltd. in January 2003. Vascular Biogenics Ltd. was founded in 2000 and is headquartered in Modi'in, Israel.

open in yahoo | open in reuters | open in google

Upgrade your FINVIZ experience